Discontinuation report TECHNIVIE
| Report ID | 29839 |
| Drug Identification Number | 02447711 |
| Brand name | TECHNIVIE |
| Common or Proper name | TECHNIVIE 12.5/75/50 MG |
| Company Name | ABBVIE CORPORATION |
| Market Status | CANCELLED POST MARKET |
| Active Ingredient(s) | Ombitasvir Paritaprevir RITONAVIR |
| Strength(s) | 12.5MG 75MG 50MG |
| Dosage form(s) | TABLET |
| Route of administration | ORAL |
| Packaging size | 4 inner cartonsx7blisters |
| ATC code | J05AX |
| ATC description | DIRECT ACTING ANTIVIRALS |
| Reason for discontinuation | Business reasons |
| Anticipated discontinuation date | |
| Actual discontinuation date | 2017-11-30 |
| Remaining supply date | 2018-06-30 |
| Discontinuation status | Discontinued |
| Discontinuation decision reversal | No |
| Information on remaining supply | Last lot available expired on JUN-30-2018. Orders can be shipped at customer request. Per AbbVie’s return policy, for your entire remaining inventory, we ask that you return product only at expiry. |
| Company comments | This decision follows Health Canada’s recent approval of MAVIRET Tablets, AbbVie’s new pan-genotypic antiviral for the treatment of adults with chronic hepatitis C virus (HCV), which will replace HOLKIRA PAK, TECHNIVIE and MODERIBA on the Canadian market. |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 8401 TRANS-CANADA HIGHWAY SAINT-LAURENT, QUEBEC CANADA H4S 1Z1 |
| Company contact information | Should you require any additional information, please contact our Customer Service Department at 1-888-704-8270. |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v4 | 2018-05-07 | French | Compare |
| v3 | 2018-05-07 | English | Compare |
| v2 | 2017-11-20 | French | Compare |
| v1 | 2017-11-20 | English | Compare |
Showing 1 to 4 of 4